Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140218 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL30786011 | 0.82 | ALDH1A1 (0.50) | KDM4EALDH1A1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL13872442 | 0.80 | MAOA (0.54) | KDM4EALDH1A1KMT2AADRB2 | |
| SCHEMBL13872475 | 0.80 | MAOA (0.54) | KDM4EALDH1A1KMT2AADRB2 | |
| SCHEMBL4774970 | 0.80 | LMNA (0.46) | KDM4EALDH1A1KMT2ATSHR | |
| SCHEMBL28466833 | 0.80 | CYP3A4 (0.37) | KDM4EALDH1A1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL15664525 | 0.80 | CYP2C19 (0.48) | KDM4EALDH1A1CYP3A4CYP2D6ATM | |
| SCHEMBL23095680 | 0.79 | KDM4E (0.40) | KDM4EALDH1A1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL22729315 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1KMT2ACYP3A4CYP2D6 | |
| SCHEMBL29169706 | 0.77 | ANPEP (0.45) | KDM4EALDH1A1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | KDM4E 1551/4885ALDH1A1 1565/4885KMT2A 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.